1. Home
  2. UNB vs MOLN Comparison

UNB vs MOLN Comparison

Compare UNB & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Union Bankshares Inc.

UNB

Union Bankshares Inc.

SELL

Current Price

$22.96

Market Cap

121.6M

Sector

Finance

ML Signal

SELL

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$3.09

Market Cap

137.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UNB
MOLN
Founded
1891
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
121.6M
137.2M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
UNB
MOLN
Price
$22.96
$3.09
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $10.22
AVG Volume (30 Days)
★ 4.1K
2.1K
Earning Date
10-21-2026
10-29-2026
Dividend Yield
★ 6.38%
N/A
EPS Growth
★ 25.52
N/A
EPS
★ 1.25
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.22
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.65
$3.40
52 Week High
$26.41
$5.36

Technical Indicators

Market Signals
Indicator
UNB
MOLN
Relative Strength Index (RSI) 38.88 39.28
Support Level N/A N/A
Resistance Level $24.16 $4.19
Average True Range (ATR) 0.40 0.11
MACD 0.02 -0.00
Stochastic Oscillator 10.26 19.54

Price Performance

Historical Comparison
UNB
MOLN

About UNB Union Bankshares Inc.

Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: